CRISPR

CRISPR3-en.gata2a.i4

ID

ZDB-CRISPR-200821-14

Previous Names

sgRNA3 targets intron 4 (1)

Target

en.gata2a.i4 (1)

Sequence

5' - GATGTCATTCGGGCCTGCCG - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
hg123	gata2a
uob101	en.gata2a.i4

Expression

Gene expression in Wild Types + CRISPR3-en.gata2a.i4

No data available

Phenotype

Phenotype resulting from CRISPR3-en.gata2a.i4

No data available

Phenotype of all Fish created by or utilizing CRISPR3-en.gata2a.i4

Phenotype	Fish	Conditions	Figures
ventral wall of dorsal aorta gata2b expression decreased amount, abnormal	en.gata2a.i4^{uob101/uob101}	standard conditions	Fig. 3 from Dobrzycki et al., 2020
pericardium edematous, abnormal	en.gata2a.i4^{uob101/uob101}	standard conditions	Fig. 6 from Dobrzycki et al., 2020
erythrocyte maturation disrupted, abnormal	en.gata2a.i4^{uob101/uob101}	standard conditions	Fig. 6 from Dobrzycki et al., 2020
neutrophil decreased amount, abnormal	en.gata2a.i4^{uob101/uob101}	standard conditions	Fig. 6 from Dobrzycki et al., 2020
dorsal aorta gata2a expression decreased distribution, abnormal	en.gata2a.i4^{uob101/uob101}	standard conditions	Fig. 2 from Dobrzycki et al., 2020
dorsal aorta runx1 expression decreased amount, abnormal	en.gata2a.i4^{uob101/uob101}	standard conditions	Fig. 3 , Fig. 5 from Dobrzycki et al., 2020
myeloid cell development disrupted, abnormal	en.gata2a.i4^{uob101/uob101}	standard conditions	Fig. 6 from Dobrzycki et al., 2020
dorsal aorta runx1 expression decreased amount, abnormal	en.gata2a.i4^{uob101/uob101}	chemical treatment: 4,4'-diaminodiphenylmethane	Fig. 5 from Dobrzycki et al., 2020
vascular endothelium gata2a expression decreased amount, abnormal	en.gata2a.i4^{uob101/uob101}	standard conditions	Fig. 2 from Dobrzycki et al., 2020
hematopoietic cell decreased amount, abnormal	en.gata2a.i4^{uob101/uob101}	standard conditions	Fig. 5 , Fig. 6 from Dobrzycki et al., 2020
hematopoietic cell decreased amount, exacerbated	en.gata2a.i4^{uob101/uob101}	chemical treatment: 4,4'-diaminodiphenylmethane	Fig. 5 from Dobrzycki et al., 2020
defense response to bacterium decreased occurrence, abnormal	en.gata2a.i4^{uob101/uob101}	standard conditions	Fig. 6 from Dobrzycki et al., 2020
thymus rag1 expression decreased amount, abnormal	en.gata2a.i4^{uob101/uob101}	standard conditions	Fig. 4 from Dobrzycki et al., 2020
dorsal aorta runx1 expression decreased amount, abnormal	en.gata2a.i4^{uob101/uob101} + MO1-gata2b	standard conditions	Fig. 5 from Dobrzycki et al., 2020
hematopoietic cell decreased amount, exacerbated	en.gata2a.i4^{uob101/uob101} + MO1-gata2b	standard conditions	Fig. 5 from Dobrzycki et al., 2020
caudal hematopoietic tissue myb expression decreased amount, abnormal	en.gata2a.i4^{uob101/uob101} + MO1-gata2b	standard conditions	Fig. 5 from Dobrzycki et al., 2020
head kidney hematopoietic multipotent progenitor cell decreased amount, abnormal	gata2a^hg123/+; gata2b^hg95/hg95; runx1^hg96/hg96	standard conditions	Figure 6. from Bresciani et al., 2021
head kidney hematopoietic multipotent progenitor cell decreased amount, abnormal	gata2a^hg123/hg123; gata2b^hg95/+; runx1^hg96/hg96	standard conditions	Figure 6. from Bresciani et al., 2021
head kidney hematopoietic multipotent progenitor cell decreased amount, abnormal	gata2a^hg123/hg123; gata2b^hg95/hg95; runx1^hg96/hg96	standard conditions	Figure 6. from Bresciani et al., 2021

Citations